Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: A study in adolescent rats with ketamine-induced model of schizophrenia

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 162-167

  Gama, Clarissa S ^a,b   Canever, Lara ^c   Panizzutti, Bruna ^a,b   Gubert, Carolina ^a,b   Stertz, Laura ^a,b   Massuda, Raffael ^a,b   Pedrini, Mariana ^a,b   de Lucena, David F ^d,e   Luca, Renata D ^c   Fraga, Daiane B ^c   Heylmann, Alexandra S ^c   Deroza, Pedro F ^c   Zugno, Alexandra I ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^d Faculdade de Medicina Christus   (Brazil)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Animal model; BDNF; Conversion to psychosis; Omega 3 polyunsaturated fatty acids; Schizophrenia; Ultra high risk population

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; MESSENGER RNA; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; GENE EXPRESSION; HIPPOCAMPUS; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT RESPONSE; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; FATTY ACIDS, OMEGA-3; HUMANS; INHIBITION (PSYCHOLOGY); INTERPERSONAL RELATIONS; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RNA, MESSENGER; SCHIZOPHRENIA; TIME FACTORS;

EID: 84866893763     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.002     Document Type: Article

References (65)

1. Adler C.M., Malhotra A.K., Elman I., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 1999, 156(10):1646-1649.
2. Amminger G.P., McGorry P.D. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology 2012, 37:309-310.
3. Amminger G.P., Schäfer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
4. Amminger G.P., Schäfer M.R., Klier C.M., et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol. Psychiatry 2011, (Dec 20, [Epub ahead of print]). 10.1038/mp. 2011.167.
5. Amminger G.P., Henry L.P., Harrigan S.M., et al. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr. Res. 2011, 131:112-119.
6. Assies J., Lieverse R., Vreken P., et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry 2001, 49(6):510-522.
7. Autry A.E., Adachi M., Nosyreva E., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 15:91-95.
8. Balanza-Martinez V., Fries G.R., Colpo G.D., et al. Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert. Rev. Neurother. 2011, 11:1029-1047.
9. Becker A., Grecksh G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1267-1277.
10. Berger G.E., Wood S.J., Wellard R.M., et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
11. Berger G.E., Wood S.J., Ross M., et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr. Pharm. Des. 2012, 18:570-575.
12. Bevilaqua L.R., Kerr D.S., Medina J.H., et al. Inhibition of hippocampal Jun N-terminal kinase. Short term memory but blocks long-term memory formation and retrieval of an inhibitory avoidance task. Eur. J. Neurosci. 2003, 17:897-902.
13. Cannon T.D., Cornblatt B., McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr. Bull. 2007, 33:661-664.
14. Cannon T.D., Cadenhead K., Cornblatt B., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65:28-37.
15. de Lima M.N., Laranja D.C., Bromberg E., et al. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav. Brain Res. 2005, 156:139-143.
16. de Oliveira L., Spiazzi C.M., Bortolin T., et al. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1003-1008.
17. de Oliveira L., Fraga D.B., De Luca R.D. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab. Brain Dis. 2011, 26:69-77.
18. Dicicco-Bloom E., Lord C., Zwaigenbaum L., et al. The developmental neurobiology of autism spectrum disorder. J. Neurosci. 2006, 26:6807-6906.
19. Farber N.B., Wozniak D.F., Price M.T., et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol. Psychiatry 1995, 38:788-796.
20. Gama C.S., Salvador M., Andreazza A.C., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:512-515.
21. Gama C.S., Andreazza A.C., Kunz, et al. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007, 420:45-48.
22. Gama C.S., Berk M., Andreazza A.C., et al. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev. Bras. Psiquiatr. 2008, 30:337-340.
23. Gama C.S., Salvador M., Andreazza A.C., et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008, 33:270-273.
24. Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat. Rev. Neurosci. 2008, 9:568-578.
25. Gratacos M., Gonzalez J.R., Mercader J.M., et al. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry 2007, 61:911-922.
26. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30:93-208.
27. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr. Res. 1994, 13:195-207.
28. Hunt M.J., Raynaud B., Gacia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol. Psychiatry 2006, 60:1206-1214.
29. Imre G., Fokkema D.S., Den Boer J.A., et al. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res. Bull. 2006, 69:338-345.
30. Izquierdo I., Barros D.M., Mello e Souza T., et al. Mechanisms for memory types differ. Nature 1998, 393:635-636.
31. Kapczinski F., Frey B.N., Andreazza A.C., et al. Increased oxidative stress as a mechanism for decreased BDNF levels in acutemanic episodes. Rev. Bras. Psiquiatr. 2008, 30:243-245.
32. Kaur T., Cadenhead K.S. Treatment implications of the schizophrenia prodrome. Curr. Top. Behav. Neurosci. 2010, 4:97-121. (Central PMCID: PMC3136161).
33. Khan M.M., Evans D.R., Gunna V., et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58:1-10.
34. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
35. Kunz M., Gama C.S., Andreazza A.C., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1677-1681.
36. Kunz M., Ceresér K.M., Goi P.D., et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011, 33:268-274.
37. Loewy R.L., Pearson R., Vinogradov S., et al. Psychosis risk screening with the Prodromal Questionnaire-brief version (PQ-B). Schizophr. Res. 2011, 129:42-46.
38. Loewy R.L., Therman S., Manninen M. Prodromal psychosis screening in adolescent psychiatry clinics. Early Interv. Psychiatry 2012, 6:69-75.
39. Mahadik S.P., Pillai A., Joshi S., et al. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 2006, 18:119-131.
40. Marshall M., Rathbone J. Early intervention for psychosis. Cochrane Database Syst. Rev. 2011, 6:CD004718.
41. McGorry P.D., Nelson B., Amminger G.P., et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70:1206-1212.
42. Mohn A.R., Gainetdinov R.R., Caron M.G., et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
43. Moldin S.O., Rubenstein J.L., Hyman S.E. Can autism speak to neuroscience?. J. Neurosci. 2006, 26:6893-6896.
44. Niesink R.J., Van Ree J.M. Involvement of opioid and dopaminergic systems in isolation-induced pinning and social grooming of young rats. Neuropharmacology 1989, 28:411-418.
45. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 2006, 86:321-322.
46. Pedrini M., Massuda R., Fries G.R., et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 2012, 46(6):819-824.
47. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr. J. Psychiatry Relat. Sci. 2008, 1:19-25.
48. Phillips L.J., Yung A.R., McGorry P.D. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust. N. Z. J. Psychiatry 2000, 34:S164-S169. (Suppl.).
49. Phillips L.J., Cotton S., Mihalopoulos C., et al. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv. Psychiatry 2009, 3:28-34.
50. Preti A., Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 2010, 123:30-36.
51. Qian L., Zhao J., Shi Y., et al. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem. Biophys. Res. Commun. 2007, 353:738-743.
52. Quevedo J., Vianna M., Zanatta M.S., et al. Involvement of mechanisms dependent on NMDA receptors, nitric oxide and protein kinase A in the hippocampus but not in the caudate nucleus in memory. Behav. Pharmacol. 1997, 8:713-717.
53. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline. Schizophr. Bull. 2004, 30(4):901-911.
54. Réus G.Z., Stringari R.B., Ribeiro K.F., et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav. Brain Res. 2011, 22:166-171.
55. Ricci V., Martinotti G., Gelfo F., et al. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. Psychopharmacology 2011, 215:143-148.
56. Roesler R., Schröder N., Vianna M.R., et al. Differential involvement of hippocampal and amygdalar NMDA receptors in contextual and aversive aspects of inhibitory avoidance memory in rats. Brain Res. 2003, 975:207-213.
57. Schneidert T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
58. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins Leukot. Essent. FattyAcids 2003, 69:367-384.
59. Tomiya M., Fukushima T., Kawai J., et al. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-d-aspartate receptor antagonist, ketamine. Biomed. Chromatogr. 2006, 33:628-633.
60. Tropea D., Capsoni S., Tongiorgi E. Mismatch between BDNF mRNA and protein expression in the developing visual cortex: the role of visual experience. Eur. J. Neurosci. 2001, 13:709-721.
61. Wu A., Ying Z., Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 2004, 21:1457-1467.
62. Yao J.K. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. Phospholipid Spectrum Disorders in Psychiatry and Neurology 2003, 193-212. Marius Press, Lancashire, UK. 2nd edition. M. Peet, I. Glen, D.F. Horrobin (Eds.).
63. Yung A.R., Nelson B. Young people at ultra high risk for psychosis: a research update. Early Interv. Psychiatry 2011, 1:52-57.
64. Yung A.R., Phillips L.J., Yuen H.P., et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004, 67:131-142.
65. Yung A.R., Yuen H.P., Berger G., et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33:673-681.